Biocompatible bacteria-derived vesicles show inherent antimicrobial activity.
Access full-text PDFOpen Access
Check access options
Check access options
Schulz et al.pdf
original manuscript with figures
Schulz et al_supplementary_info.pdf
corrigendum to Schulz et al
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractUp to 25,000 people die each year from resistant infections in Europe alone, with increasing incidence. It is estimated that a continued rise in bacterial resistance by 2050 would lead up to 10 million annual deaths worldwide, exceeding the incidence of cancer deaths. Although the design of new antibiotics is still one way to tackle the problem, pharmaceutical companies investigate far less into new drugs than 30 years ago. Incorporation of antibiotics into nanoparticle drug carriers ("nanoantibiotics") is currently investigated as a promising strategy to make existing antibiotics regain antimicrobial strength and overcome certain types of microbial drug resistance. Many of these synthetic systems enhance the antimicrobial effect of drugs by protecting antibiotics from degradation and reducing their side effects. Nevertheless, they often cannot selectively target pathogenic bacteria and - due to their synthetic origin - may induce side-effects themselves. In this work, we present the characterisation of naturally derived outer membrane vesicles (OMVs) as biocompatible and inherently antibiotic drug carriers. We isolated OMVs from two representative strains of myxobacteria, Cystobacter velatus Cbv34 and Sorangiineae species strain SBSr073, a bacterial order with the ability of lysing other bacterial strains and currently investigated as sources of new secondary metabolites. We investigated the myxobacterias' inherent antibacterial properties after isolation by differential centrifugation and purification by size-exclusion chromatography. OMVs have an average size range of 145-194 nm. We characterised their morphology by electron cryomicroscopy and found that OMVs are biocompatible with epithelial cells and differentiated macrophages. They showed a low endotoxin activity comparable to those of control samples, indicating a low acute inflammatory potential. In addition, OMVs showed inherent stability under different storage conditions, including 4 °C, -20 °C, -80 °C and freeze-drying. OMV uptake in Gram-negative model bacterium Escherichia coli (E. coli) showed similar to better incorporation than liposome controls, indicating the OMVs may interact with model bacteria via membrane fusion. Bacterial uptake correlated with antimicrobial activity of OMVs as measured by growth inhibition of E. coli. OMVs from Cbv34 inhibited growth of E. coli to a comparable extent as the clinically established antibiotic gentamicin. Liquid-chromatography coupled mass spectrometry analyses revealed the presence of cystobactamids in OMVs, inhibitors of bacterial topoisomerase currently studied to treat different Gram-negative and Gram-positive pathogens. This work, may serve as an important basis for further evaluation of OMVs derived from myxobacteria as novel therapeutic delivery systems against bacterial infections.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
JournalJournal of Controlled Release
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Myxobacteria-Derived Outer Membrane Vesicles: Potential Applicability Against Intracellular Infections.
- Authors: Goes A, Lapuhs P, Kuhn T, Schulz E, Richter R, Panter F, Dahlem C, Koch M, Garcia R, Kiemer AK, Müller R, Fuhrmann G
- Issue date: 2020 Jan 12
- Outer Membrane Vesicles Protect Gram-Negative Bacteria against Host Defense Peptides.
- Authors: Balhuizen MD, van Dijk A, Jansen JWA, van de Lest CHA, Veldhuizen EJA, Haagsman HP
- Issue date: 2021 Aug 25
- Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy.
- Authors: Huang W, Meng L, Chen Y, Dong Z, Peng Q
- Issue date: 2022 Mar 1
- Outer membrane vesicles from β-lactam-resistant Escherichia coli enable the survival of β-lactam-susceptible E. coli in the presence of β-lactam antibiotics.
- Authors: Kim SW, Park SB, Im SP, Lee JS, Jung JW, Gong TW, Lazarte JMS, Kim J, Seo JS, Kim JH, Song JW, Jung HS, Kim GJ, Lee YJ, Lim SK, Jung TS
- Issue date: 2018 Mar 29
- Interaction of myxobacteria-derived outer membrane vesicles with biofilms: antiadhesive and antibacterial effects.
- Authors: Goes A, Vidakovic L, Drescher K, Fuhrmann G
- Issue date: 2021 Sep 14